Beta Bionics, Inc. (BBNX) Common Equity (2023 - 2026)

Beta Bionics (BBNX) has 4 years of Common Equity data on file, last reported at $271.2 million in Q1 2026.

• Quarterly Common Equity fell 13.55% year-over-year to $271.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $271.2 million (down 13.55% YoY) and the FY2025 annual result came in at $287.6 million, up 217.22% from the prior year.
• Common Equity retreated to $271.2 million in Q1 2026 per BBNX's latest filing, from $287.6 million in the prior quarter.
• The five-year high for Common Equity was $313.8 million in Q1 2025, with the low at -$245.4 million in Q4 2024.
• Average Common Equity over 4 years is $35.6 million, with a median of $34.1 million recorded in 2023.
• Year-over-year, Common Equity declined 20.8% in 2024 and surged 246.39% in 2025.
• Beta Bionics' Common Equity stood at -$203.1 million in 2023, then fell by 20.8% to -$245.4 million in 2024, then surged by 217.22% to $287.6 million in 2025, then retreated by 5.69% to $271.2 million in 2026.
• Business Quant data shows BBNX's Common Equity at $271.2 million in Q1 2026, $287.6 million in Q4 2025, and $294.8 million in Q3 2025.